Table 3.

hSBA performed on wild-type and nadR knockout mutant selected strains^a

Strain	Study 1 (adults) SBA titer		Study 2 (infants) SBA titer
	Preimmune	4CMenB post 3b	Routine	4CMenB post 4c
5/99	<4	256	<4	>512
961-5945	<4	16	<2	16
961-5945 nadR KO	<4	>512	<4	>512
LNP17094	<4	16	<2	16
LNP17094 nadR KO	<4	>512	<4	>512
B3937	<4	8	<2	<2
B3937 nadR KO	<4	>512	8	>512
M10574	<4	32	<2	64
M10574 nadR KO	<4	>512	<4	>512
M14933	<4	16	<2	32
M14933 nadR KO	<4	>512	8	>512
NGP165	<4	<4	2	4
NGP165 nadR KO	<4	>256	4	>256

^aStrains were considered killed if pooled sera from different age groups who received the 4CMenB achieved an SBA titer ≥ 8.

^b4CMenB post 3, 3 doses of the vaccine given at 0, 2, and 6 months.

^c4CMenB post 4, 3 doses of the vaccine given at 0, 2, and 6 months plus 1 boost between 12 and 24 months.